HDAC9 and medulloblastoma: In addition, we demonstrate how a novel orally available benzamide-type HDAC inhibitor, termed 4SC-202, significantly reduces the viability of medulloblastoma in culture, and lay the groundwork for potential preclinical work by using 4SC-202 in preclinical models of pediatric medulloblastoma.